• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
  • For Subscribers

Trendingnow

1

Welcome to the singularity

2

AT&T CEO says 200,000 fiber and telecommunications workers are needed thanks to AI—they’re stable, $70K-paying jobs that don’t require a degree

3

TJMaxx’s parent company is spending one-third of its $463 million in tariff refunds on corporate bonuses—and it’s not the only one

1

Welcome to the singularity

2

AT&T CEO says 200,000 fiber and telecommunications workers are needed thanks to AI—they’re stable, $70K-paying jobs that don’t require a degree

3

TJMaxx’s parent company is spending one-third of its $463 million in tariff refunds on corporate bonuses—and it’s not the only one
Vertex Pharmaceuticals

Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%

By
Jeffrey Leiden
Jeffrey Leiden
Down Arrow Button Icon
By
Jeffrey Leiden
Jeffrey Leiden
Down Arrow Button Icon
November 22, 2026, 8:30 AM ET
Jeffrey Leiden, executive chairman of Vertex Pharmaceuticals.
Jeffrey Leiden is executive chairman and former CEO of Vertex Pharmaceuticals.Courtesy of Vertex Pharmaceuticals
Google source logo
Add Fortune on Google for similar content.

Corporate America is locked in an innovation arms race – a race that is turning out very few winners. Companies are spending billions on R&D, acquisitions and new technologies, operating on the seemingly intuitive premise that making more bets is the best way to approach the uncertainty of the future.

Recommended Video

But more bets don’t necessarily produce more successes.

There’s no more extreme example of this problem than pharmaceuticals and biotech. It takes an average of 10 to 15 years for a drug to go from the lab to regulatory approval. And more than 90% of drugs that enter clinical development fail. Just look at the headlines: one of the world’s largest pharmaceutical companies recently suffered three drug trial failures in a single week despite an enormous R&D budget, many talented scientists and a deep pipeline.

But this problem is far from unique to healthcare. In consumer tech, many startups flame out after a single hit; in automotive, EV pioneers are routinely outpaced by fast followers; digital investments in retail often fail to translate into customer growth.

The instinctive response when innovation fails is to do more of it: fund more projects, pursue more ideas, make more acquisitions and place more bets. If innovation is inherently unpredictable, the thinking goes, the best way to improve your chances of success is to increase the number of shots you take.

This kind of thinking is completely backward. It’s not about the shots. It’s about the target.

Imagine entering a darts tournament and throwing five consecutive bull’s-eyes, only to discover that you have been throwing at the wrong board. Your accuracy doesn’t matter. You’ve lost.

More activity creates the appearance of innovation without improving its effectiveness. I learned this the hard way.

When I joined Vertex Pharmaceuticals in 2009, the company had spent two decades investing heavily in R&D across 20 different programs. Yet, it produced only a single breakthrough product, which was rendered obsolete just two and a half years later with the approval of a better and more tolerable treatment discovered by another company.

When we examined why drug development failed so frequently, the problem wasn’t that scientists had failed to create a drug that hit its intended biological target. The problem was that they had chosen the wrong target in the first place.

Building a Smaller Sandbox

The solution was to take away choices, constraining ourselves to a “sandbox” of diseases with genetically- or pharmacologically-validated targets where we believed we had a much higher probability of success.

Most importantly, both R&D and business development had to stay inside the same sandbox. A fascinating scientific discovery or enticing acquisition wasn’t enough. If it didn’t fit our strategy or if we didn’t have a validated target to address, we walked away.

That last part may be the most difficult lesson for any leader. Companies often celebrate the ability to say yes to innovation. Sustainable innovators also become very good at saying no. Focus and strategy don’t limit innovation, they accelerate it.

Stop Treating Innovation as an R&D Department

A thriving innovation program requires many parts of an organization working in harmony. Yet companies unintentionally divide innovation into functional silos, with each group incentivized differently and no one focused on the big picture.

Researchers discover something and hand it to developers. Developers hand it to manufacturing. Eventually, commercial teams are asked to sell it. Business development may operate on a separate track entirely, hunting for external opportunities.

But a brilliant invention that cannot be efficiently developed, manufactured or commercialized isn’t a successful innovation.

To break down internal silos, leaders from research, development, regulatory, manufacturing, commercial and other key business units should be included in decisions about new product development from the earliest stages of the innovation process. And internal and external innovation must be tightly integrated into the same strategy. Business development can’t be given permission to roam the universe looking for any interesting assets; partnerships and acquisitions must reinforce the same strategy, diseases, and targets where a company believes it has a high probability of success.

Innovation shouldn’t be measured by how many ideas an organization generates. It should be judged by how effectively the entire organization converts its best ideas into products that meet people’s needs and create meaningful value.

Success Should Lead to More Serial Innovation

Once innovation succeeds, companies tend to become complacent and stop innovating to create better and better medicines for the same disease. Our experience seeing one of our breakthrough drugs quickly made obsolete by an innovative competitor created a sense of urgency, and even some paranoia, which drove our organization to continuously try to “out-innovate ourselves.”

Being first doesn’t guarantee long term success. Competitors will learn from your breakthroughs and improve on the foundations you laid. We decided that if someone was going to build a better second-generation product, it should be us.

The results were dramatic. Vertex went on to develop multiple transformative medicines, including 5 medicines that alter the course of cystic fibrosis for 95% of patients and, with CRISPR Therapeutics, the first FDA-approved human gene-editing therapy for patients with severe Sickle Cell Disease and transfusion-dependent B-thalassemia. More recently we created a completely new class of non-opioid medicines for moderate to severe acute pain.

Even more important to me is what happened to the odds. Our R&D success rate, measured by positive Phase II proof of concept, exceeded 70% across six diseases — far above the 10% to 20% industry average. We didn’t eliminate risk. Innovation can’t exist without risk. But we became much more deliberate about which risks were worth taking and therefore more successful.

Innovation Requires Discipline

Before approving the next project, acquisition or moonshot, leadership teams should ask themselves an important set of questions: Do we understand why innovation has failed here before? Are we pursuing opportunities where we possess a genuine advantage? What evidence tells us that the underlying problem is solvable? Does this opportunity reinforce our existing capabilities – or merely distract from them? And, perhaps hardest of all, what are we willing to stop doing so that our best ideas have the resources to succeed?

The innovation economy has conditioned leaders to admire the size of the pipeline, the number of experiments and the volume of bets. Those are measures of activity, not success.

The companies that sustainably innovate will not be the ones willing to make the most bets. They’ll be the ones that understand their odds better than anyone else and have the discipline to walk away when those odds aren’t good enough.

The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune. This headline has been updated to resolve a discrepancy with the text.

About the Author
By Jeffrey Leiden
See full bioRight Arrow Button Icon
Google source logo
Add Fortune on Google for similar content.

Latest in


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Jeffrey Leiden, M.D., Ph.D., is executive chairman of Vertex Pharmaceuticals. He is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. He previously served as Vertex’s president, chief executive officer and chairman from 2012 through March 2020, and has been a member of Vertex’s board since July 2009. Under his leadership, Vertex delivered the first and only medicines to treat the underlying cause of cystic fibrosis for patients with certain forms of the disease, including Kalydeco, Orkambi and Trikafta.

    Dr. Leiden serves as lead independent director of Massachusetts Mutual Life Insurance Company, chairman of Odyssey Therapeutics and chairman of Casana. He is also a member of the MIT CEO Advisory Board and a director of the Massachusetts Competitive Partnership, and serves on the Massachusetts Governor’s Digital Healthcare Council, Governor’s Task Force on Artificial Intelligence and Governor’s STEM Advisory Council. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.


    Recommended For You

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.